AC
AUPH icon

Apogem Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Apogem Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,009
Closed -$130K – 189
2021
Q2 		$130K Sell
10,009
-17,751
-64% -$226K 0.08% 174
2021
Q1 		$360K Sell
27,760
-3,270
-11% -$47.4K 0.24% 128
2020
Q4 		$429K Buy
+31,030
New +$452K 0.29% 104

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Apogem Capital's AUPH Position: Q3 2021 in Review

Apogem Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 10,009 shares — an estimated $130K sold.

Apogem Capital first reported a position in AUPH in Q4 2020 and held it in 3 quarters. The position peaked at $429K in Q4 2020. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • Apogem Capital reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Apogem Capital sold 10,009 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $130K.
  • Apogem Capital first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Apogem Capital's Aurinia Pharmaceuticals position peaked at $429K in Q4 2020.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Apogem Capital's 13F filing for Q3 2021, filed 15 Nov 2021.